These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 21710324)

  • 1. Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection.
    Tanimoto Y; Tashiro H; Aikata H; Amano H; Oshita A; Kobayashi T; Kuroda S; Tazawa H; Takahashi S; Itamoto T; Chayama K; Ohdan H
    Ann Surg Oncol; 2012 Feb; 19(2):418-25. PubMed ID: 21710324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival.
    Ishikawa T; Higuchi K; Kubota T; Seki K; Honma T; Yoshida T; Kamimura T
    Hepatogastroenterology; 2012; 59(114):529-32. PubMed ID: 22024226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma.
    Lee D; Chung YH; Kim JA; Park WH; Jin YJ; Shim JH; Ryu SH; Jang MK; Yu E; Lee YJ
    Cancer; 2013 Jun; 119(12):2239-46. PubMed ID: 23564564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma.
    Hagihara H; Nouso K; Kobayashi Y; Iwasaki Y; Nakamura S; Kuwaki K; Toshimori J; Miyatake H; Ohnishi H; Shiraha H; Yamamoto K
    Int J Clin Oncol; 2011 Jun; 16(3):210-20. PubMed ID: 21152943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sustained virological response to interferon therapy for hepatitis C to the hepatectomy for primary hepatocellular carcinoma.
    Tsujita E; Maeda T; Kayashima H; Harada N; Tsutsui S; Matsuda H; Kinjo N; Ikeda Y; Morita M; Ishida T
    Hepatogastroenterology; 2015; 62(137):157-63. PubMed ID: 25911888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
    Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
    Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.
    Harada N; Hiramatsu N; Oze T; Tatsumi T; Hayashi N; Takehara T
    J Med Virol; 2015 Jul; 87(7):1199-206. PubMed ID: 25772024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Sustained Virological Response to Interferon Therapy on Recurrence of Hepatitis C Virus-Related Hepatocellular Carcinoma.
    Shinkawa H; Hasegawa K; Arita J; Akamatsu N; Kaneko J; Sakamoto Y; Kokudo N
    Ann Surg Oncol; 2017 Oct; 24(11):3196-3202. PubMed ID: 28707053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
    Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K
    J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.
    Chen LT; Chen MF; Li LA; Lee PH; Jeng LB; Lin DY; Wu CC; Mok KT; Chen CL; Lee WC; Chau GY; Chen YS; Lui WY; Hsiao CF; Whang-Peng J; Chen PJ;
    Ann Surg; 2012 Jan; 255(1):8-17. PubMed ID: 22104564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of adjuvant interferon therapy on hepatitis b/c virus-related hepatocellular carcinoma after curative therapy - meta-analysis.
    Xu J; Li J; Chen J; Liu ZJ
    Adv Clin Exp Med; 2015; 24(2):331-40. PubMed ID: 25931368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum antibody titers against hepatitis C virus and postoperative intrahepatic recurrence of hepatocellular carcinoma.
    Uemura M; Sasaki Y; Yamada T; Gotoh K; Eguchi H; Yano M; Ohigashi H; Ishikawa O; Imaoka S
    Ann Surg Oncol; 2014 May; 21(5):1719-25. PubMed ID: 24464342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-α therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus-related hepatocellular carcinoma.
    Qu LS; Jin F; Huang XW; Shen XZ
    J Surg Oncol; 2010 Dec; 102(7):796-801. PubMed ID: 20886584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
    Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.
    Cardoso AC; Moucari R; Figueiredo-Mendes C; Ripault MP; Giuily N; Castelnau C; Boyer N; Asselah T; Martinot-Peignoux M; Maylin S; Carvalho-Filho RJ; Valla D; Bedossa P; Marcellin P
    J Hepatol; 2010 May; 52(5):652-7. PubMed ID: 20346533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second hepatectomy for recurrent hepatocellular carcinoma achieved sustained virological response to interferon therapy for hepatitis C.
    Tsujita E; Yamashita Y; Takeishi K; Maeda T; Takaki S; Mori N; Aisaka Y; Furukawa Y; Shirabe K; Ishida T; Maehara Y
    Hepatogastroenterology; 2013; 60(128):2048-54. PubMed ID: 24088310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy after curative treatment for hepatocellular carcinoma.
    Kudo M
    Oncology; 2011; 81 Suppl 1():50-5. PubMed ID: 22212936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma.
    Hsu YC; Ho HJ; Wu MS; Lin JT; Wu CY
    Hepatology; 2013 Jul; 58(1):150-7. PubMed ID: 23389758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma.
    Uenishi T; Nishiguchi S; Tanaka S; Yamamoto T; Takemura S; Kubo S
    J Surg Oncol; 2008 Oct; 98(5):358-62. PubMed ID: 18646001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus.
    Hung CH; Lee CM; Wang JH; Tung HD; Chen CH; Lu SN
    J Gastroenterol Hepatol; 2005 Oct; 20(10):1553-9. PubMed ID: 16174073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.